Costa Rica's medical-device exports reached US$8.178 billion in January–September 2026, up 1.05% from a year earlier, La Nación reported on 13 November using Procomer figures. The United States receives 64% of the country's exports in the sector, making American manufacturing requirements central to the commercial route. The figures measure sales growth, not the effect of any individual regulation.1
The regulatory framework changed on 2 February 2026. The US Food and Drug Administration's Quality Management System Regulation, or QMSR, incorporated ISO 13485:2016, an international standard for medical-device quality management. The FDA says the change aligns its framework with other regulators and supports consistent design, production and controls throughout a product's life. It also expressly requires risk management.2
International alignment still leaves American requirements
The rule applies to manufacturers of finished devices intended for commercial distribution. Its definition can cover products capable of functioning even before packaging, labelling or sterilisation, and certain accessories count as finished devices. Where the incorporated standard conflicts with American legislation or implementing regulations, the American provisions prevail. This makes the scope of a plant's products relevant to its compliance obligations.2
CINDE, Costa Rica's private investment-promotion agency, describes a manufacturing base that extends beyond simple disposable products. Its current sector review identifies catheters, heart valves, neurovascular devices and orthopaedic implants among the country's capabilities. It reports 70 local establishments registered with the FDA in 2026 and says most plants operate quality systems certified under ISO 13485.3
The agency describes the sector's products as including:3
dispositivos Clase II y III
Class II and III devices.3
CINDE also identifies original-equipment manufacturers, contract manufacturers and specialised component suppliers within the cluster. That range matters for production transfers: the local industry includes businesses making the final device and businesses supplying the inputs and processes used to manufacture it. Its description establishes industrial capabilities, rather than promising that every new investment immediately becomes an export shipment.3
Certification does not replace inspection
The FDA's implementation guidance says an ISO certificate does not exempt a manufacturer from an FDA inspection. American inspections assess compliance with US regulations and are scheduled according to risk. The voluntary Medical Device Single Audit Program remains available, but its audit procedures are separate from the FDA's inspection process.4
Inspectors can also examine management reviews, quality audits and supplier-audit reports that were previously exempt from review under the older regulation. Records created before the transition can be examined when assessing the manufacturer's quality system. For exporters, the practical requirement therefore includes accessible evidence about suppliers and internal oversight, alongside the physical manufacturing process.4
CINDE's Vanessa Gibson told La Nación that regulatory validation and production transfers often take several quarters before investments generate exportable output. The next industrial test is how quickly those projects translate into shipments; the reported slowdown does not establish that the quality-rule transition caused it.1